Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kelong capsule for nonalcoholic fatty liver disease
ChiCTR2200061319Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Jun 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Kelong capsule group with Placebo group (2 arms). Primary endpoints: Liver CAP response and ALT response. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
Kehuang capsule
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2200061319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061319.